Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced a correction to the registration link for their upcoming presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, featuring CEO and Chairman Robert Bitterman, is scheduled for Wednesday, October 23, 2024, at 12 PM EDT.
Stakeholders, investors, and other interested parties are invited to register and attend this live event. The presentation will include a live Q&A session. A replay of the event will be available on the Renmark Financial Communications Inc. website. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), un'azienda biofarmaceutica in fase clinica, ha annunciato una correzione al link di registrazione per la loro prossima presentazione nella serie di eventi virtuali 'Non-Deal Roadshow' organizzata da Renmark Financial Communications. L'evento, che vedrà la partecipazione del CEO e Presidente Robert Bitterman, è programmato per mercoledì 23 ottobre 2024, alle 12 PM EDT.
Stakeholder, investitori e altre parti interessate sono invitati a registrarsi e partecipare a questo evento dal vivo. La presentazione includerà una sessione di domande e risposte in diretta. Una registrazione dell'evento sarà disponibile sul sito web di Renmark Financial Communications Inc. Phio Pharmaceuticals è specializzata nella tecnologia di silenziamento genico INTASYL® siRNA, progettata per migliorare l'efficacia delle cellule immunitarie nell'eliminazione delle cellule tumorali.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), una empresa de biotecnología en etapa clínica, ha anunciado una corrección en el enlace de registro para su próxima presentación en la serie de eventos virtuales 'Non-Deal Roadshow' de Renmark Financial Communications. El evento, encabezado por el CEO y Presidente Robert Bitterman, está programado para el miércoles 23 de octubre de 2024, a las 12 PM EDT.
Los interesados, inversionistas y otras partes interesadas están invitados a registrarse y asistir a este evento en vivo. La presentación incluirá una sesión de preguntas y respuestas en vivo. La repetición del evento estará disponible en el sitio web de Renmark Financial Communications Inc. Phio Pharmaceuticals se especializa en la tecnología de silenciamiento génico INTASYL® siRNA, diseñada para mejorar la efectividad de las células inmunitarias en la eliminación de células tumorales.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), 임상 단계의 생명공학 회사가 Renmark Financial Communications의 가상 '비거래 로드쇼' 시리즈에 대한 다가오는 발표의 등록 링크 수정을 발표했습니다. CEO 및 회장 로버트 비터맨이 참여하는 이 행사는 2024년 10월 23일 수요일 오후 12시 EDT로 예정되어 있습니다.
이벤트에 관심이 있는 이해관계자, 투자자 및 기타 관련자들은 등록하여 이 라이브 이벤트에 참석하도록 초대받습니다. 발표에는 라이브 Q&A 세션이 포함됩니다. 이벤트의 다시 보기 영상은 Renmark Financial Communications Inc. 웹사이트에서 제공될 예정입니다. Phio Pharmaceuticals는 종양 세포를 죽이는 면역 세포의 효과를 강화하기 위해 설계된 INTASYL® siRNA 유전자 침묵 기술를 전문으로 합니다.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), une entreprise de biotechnologie en phase clinique, a annoncé une correction du lien d'inscription pour sa prochaine présentation dans la série 'Non-Deal Roadshow' virtuelle de Renmark Financial Communications. L'événement, avec le PDG et Président Robert Bitterman, est prévu pour mercredi 23 octobre 2024, à 12h00 EDT.
Les parties prenantes, investisseurs et autres personnes intéressées sont invitées à s'inscrire et à assister à cet événement en direct. La présentation comprendra une session de questions-réponses en direct. Un replay de l'événement sera disponible sur le site Web de Renmark Financial Communications Inc. Phio Pharmaceuticals se spécialise dans la technologie de silençage génique INTASYL® siRNA, conçue pour améliorer l'efficacité des cellules immunitaires à tuer les cellules tumorales.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), ein biopharmazeutisches Unternehmen in klinischer Phase, hat eine Korrektur des Registrierungslinks für ihre bevorstehende Präsentation in der virtuellen 'Non-Deal Roadshow'-Reihe von Renmark Financial Communications bekannt gegeben. Die Veranstaltung, die CEO und Vorsitzenden Robert Bitterman präsentieren wird, ist für Mittwoch, den 23. Oktober 2024, um 12 Uhr EDT geplant.
Wirtschaftliche Stakeholder, Investoren und andere Interessierte sind eingeladen, sich zu registrieren und an dieser Live-Veranstaltung teilzunehmen. Die Präsentation wird eine Live-Q&A-Session enthalten. Eine Wiedergabe der Veranstaltung wird auf der Website von Renmark Financial Communications Inc. verfügbar sein. Phio Pharmaceuticals spezialisiert sich auf die INTASYL® siRNA Gen-Silencing-Technologie, die entwickelt wurde, um die Effektivität von Immunzellen beim Töten von Tumorzellen zu erhöhen.
- None.
- None.
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT
Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Wednesday, October 23, 2024, at 12 PM EDT. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.
Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Correction to Registration Link:
REGISTER HERE: Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications
If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. In non-systemic applications, INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227064
FAQ
When is Phio Pharmaceuticals (PHIO) presenting at the Renmark Financial Communications Virtual Non-Deal Roadshow?
Who will be presenting for Phio Pharmaceuticals (PHIO) at the Virtual Non-Deal Roadshow?
How can I register for Phio Pharmaceuticals' (PHIO) presentation at the Virtual Non-Deal Roadshow?
Will there be a replay available of Phio Pharmaceuticals' (PHIO) presentation?
